NasdaqGS:GLUEBiotechs
A Look At Monte Rosa Therapeutics (GLUE) Valuation After Positive MRT-8102 Phase 1 Interim Data
Monte Rosa Therapeutics (GLUE) just reported positive interim Phase 1 data for MRT-8102, with strong target engagement, reductions in hsCRP and IL-6, and a favorable safety profile that appears to have caught investors' attention.
See our latest analysis for Monte Rosa Therapeutics.
The positive MRT-8102 update lands after a very strong run in the shares, with a 30-day share price return of 57.27% and a 90-day share price return of 161.39%. The 1-year total shareholder return is extremely...